Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine

Click to increase image sizeClick to decrease image size

Acknowledgements

We thank the patients, their caregivers, and members of the study team involved in this trial.

Clinical trial registration information: https://clinicaltrials.gov/ct2/show/NCT03404193

Institutional review board approval and ethics committee clearance: obtained.

Prior presentation: Presented as a poster in the European Haematology Association Annual Conference 2021.

Disclosure statement

SV: none. AM: research funding from Celgene Corporation. CDD: personal fees from Abbvie, personal fees from Agios, personal fees from Novartis, personal fees from ImmuneOnc, personal fees from Daiichi Sankyo, personal fees from Celgene, personal fees from Jazz, personal fees from Notable Labs, outside the submitted work. SL: none. NGD: reports grant from Abbvie, Genentech, Astellas, Daiichi-Sankyo, Pfizer, BMS, Immunogen, Novimmune, Forty-seven; personal fees from Abbvie, Genentech, Astellas, Daiichi-Sankyo, Pfizer, BMS, Immunogen, Jazz pharmaceuticals, Trillium, Forty-seven, Gilead, Kite, Novartis. TMK: none. CRR: none. YA: none. MO: none. KS: none. NJS: reports grant from Takeda Oncology, Astellas; Personal fees from Takeda Oncology, AstraZeneca, Amgen. KT: has received personal fees for service on advisory boards of Symbio Pharmaceuticals, GSK, Celgene. MY: none. FR: none. HMK: grants and other from AbbVie, grants and other from Agios, grants and other from Amgen, grants from Ariad, grants from Astex, grants from BMS, from Cyclacel, grants from Daiichi-Sankyo, grants and other from Immunogen, grants from Jazz Pharma, grants from Novartis, grants and other from Pfizer, other from Actinium, other from Takeda, outside the submitted work. MYK: has received grants from NIH, NCI, Abbvie, Genentech, Stemline Therapeutics, Forty-Seven, Eli Lilly, Cellectis, Calithera, Ablynx, Astra Zeneca; Consulting/honorarium from AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji; clinical trial support from Ascentage; stocks/royalties in Reata Pharmaceutical.

Data availability statement

At this time, we will not be able to share individual patient level data outside of our institution.

Additional information

Funding

This study was supported in part by the MD Anderson Cancer Center Support Grant CA016672 from the National Cancer Institute and the Research Project Grant Program (R01CA235622) from the National Institutes of Health.